Zenas BioPharma, Inc. - Common Stock (ZBIO)
12.11
+0.17 (1.42%)
NASDAQ · Last Trade: Jun 11th, 5:16 PM EDT
Detailed Quote
Previous Close | 11.94 |
---|---|
Open | 11.94 |
Bid | 11.65 |
Ask | 12.85 |
Day's Range | 11.65 - 12.50 |
52 Week Range | 5.830 - 26.25 |
Volume | 1,080,192 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 144,570 |
Chart
About Zenas BioPharma, Inc. - Common Stock (ZBIO)
Zenas Biopharma Inc is a biotechnology company focused on developing innovative therapies for patients with rare diseases and unmet medical needs. The company leverages advanced research and scientific expertise to create targeted treatments aimed at improving health outcomes. With a commitment to addressing complex medical challenges, Zenas Biopharma strives to enhance the quality of life for individuals living with debilitating conditions through its cutting-edge drug development programs and collaborations within the biopharmaceutical industry. Read More
News & Press Releases
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · June 10, 2025
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · June 10, 2025
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ibotta, Inc. (NYSE:IBTA), NET Power, Inc. (NYSE:NPWR), Zenas BioPharma, Inc. (NASDAQ:ZBIO), and Avis Budget Group, Inc. (NASDAQ:CAR). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · June 9, 2025

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · June 6, 2025

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ibotta, Inc. (NYSE:IBTA), NET Power, Inc. (NYSE:NPWR), Zenas BioPharma, Inc. (NASDAQ:ZBIO), and BigBear.ai Holdings, Inc. (NYSE:BBAI). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · June 2, 2025

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · June 2, 2025

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · June 2, 2025

NEW YORK, June 01, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · June 1, 2025

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · May 29, 2025

WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced management’s presentation at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 1:25 p.m. ET.
By Zenas BioPharma · Via GlobeNewswire · May 29, 2025

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · May 28, 2025
NEW YORK, May 26, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · May 26, 2025
NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · May 23, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options.
By Faruqi & Faruqi LLP · Via GlobeNewswire · May 23, 2025
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · May 22, 2025
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Avis Budget Group, Inc. (NASDAQ:CAR), Civitas Resources, Inc. (NYSE: CIVI), Open Lending Corporation (NASDAQ:LPRO), and Zenas BioPharma, Inc. (NASDAQ:ZBIO). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · May 21, 2025
NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · May 18, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · May 18, 2025
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -
By Zenas BioPharma · Via GlobeNewswire · May 15, 2025
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ibotta, Inc. (NYSE:IBTA), NET Power, Inc. (NYSE:NPWR), Zenas BioPharma, Inc. (NASDAQ:ZBIO) and BigBear.ai Holdings, Inc. (NYSE:BBAI). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · May 14, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · May 14, 2025
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · May 13, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · May 11, 2025
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · May 9, 2025
NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Avis Budget Group, Inc. (NASDAQ:CAR), NET Power, Inc. (NYSE:NPWR), Open Lending Corporation (NASDAQ:LPRO), and Zenas BioPharma, Inc. (NASDAQ:ZBIO). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · May 7, 2025